Abstract
Purpose: Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite recent advances in SK1 inhibitors synthesis and validation, their clinical safety and chemosensitising options are not well described. In this study, we have designed, synthesised and tested a new specific SK1 inhibitor with a low toxicity profile.
Methods: Field template molecular modelling was used for compound design. Lead compounds were tested in cell and mouse cancer models.
Results: Field template analysis of three known SK1 inhibitors, SKI-178, 12aa and SK1-I, was performed and compound screening identified six potential new SK1 inhibitors. SK1 activity assays in both cell-free and in vitro settings showed that two compounds were effective SK1 inhibitors. Compound SK-F has potently decreased cancer cell viability in vitro and sensitised mouse breast tumours to docetaxel (DTX) in vivo, without significant whole-body toxicity.
Conclusion: Through field template screening, we have identified a new SK1 inhibitor, SK-F, which demonstrated antitumour activity in vitro and in vivo without overt toxicity when combined with DTX.
Methods: Field template molecular modelling was used for compound design. Lead compounds were tested in cell and mouse cancer models.
Results: Field template analysis of three known SK1 inhibitors, SKI-178, 12aa and SK1-I, was performed and compound screening identified six potential new SK1 inhibitors. SK1 activity assays in both cell-free and in vitro settings showed that two compounds were effective SK1 inhibitors. Compound SK-F has potently decreased cancer cell viability in vitro and sensitised mouse breast tumours to docetaxel (DTX) in vivo, without significant whole-body toxicity.
Conclusion: Through field template screening, we have identified a new SK1 inhibitor, SK-F, which demonstrated antitumour activity in vitro and in vivo without overt toxicity when combined with DTX.
| Original language | English |
|---|---|
| Pages (from-to) | 33–43 |
| Number of pages | 11 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 172 |
| Issue number | 1 |
| Early online date | 24 Jul 2018 |
| DOIs | |
| Publication status | Published - Nov 2018 |
Keywords
- Sphingosine kinase 1
- Molecular field template
- Kinase inhibitor
- Chemosensitisation
- Docetaxel
- Breast cancer
- POTENTIAL THERAPEUTIC TARGET
- PROSTATE-CANCER CELL
- BREAST-CANCER
- PROTEASOMAL DEGRADATION
- FTY720
- GROWTH
- EXPRESSION
- SPHINGOSINE-1-PHOSPHATE
- IMMUNOMODULATOR
- 1-PHOSPHATE
Access to Document
- Published manuscript
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.